Introduction
Histone deacetylases (HDACs) are a class of proteases widely existing in eukaryotic cells. Up to now, there are 18 human HDACs that have been identified. On the basis of sequence similarity, intracellular localization and tissue specific distribution, human HDACs have been classified into 4 groups (1). Class I HDACs (HDAC1, 2, 3, and 8) located in the nucleus are expressed widely in various tissues and inhibit gene expression. Based on the sequence homology and domain organization, Class II HDACs are divided into two sub-groups, Class IIa (HDAC4, 5, 7, and 9) and Class IIb (HDAC6 and 10), and may be associated with cell differentiation (2, 3) . Class IIa HDACs shuttle between the cytoplasm and nucleus; Class IIb HDACs situated in cytoplasm typically contain double zinc catalytic centers. Class IV HDAC (HDAC11) is comprised of a unique member HDAC11 just because of the specific structure of HDAC11 (4) . In contrast to all of the above Zn 2+ dependent HDACs, Class III (Sir1-7) homologous to the yeast Sir2 family of proteins are also called sirtuins (2, 3, 5) .
The nucleosome, which is the basic structural unit of eukaryotic chromosomes, consists of an octamer (an H3-H4 tetramer and two H2A-H2B dimers) and DNA (deoxyribonucleic acid) wrapping around the octamer (6) . It is the HDACs that catalyze the cleavage of the N-acetyl group from acetylated lysine residues located on the tails of the core nucleosomal histones (7) . Together with the histone acetyl transferases, HDACs regulate the balance of acetylation and deacetylation (8) . When HDACs are more active, histone proteins are deacetylated and bind tighter to DNA, thus it is difficult for transcriptional regulatory proteins to combine with DNA, leading to the inhibition of gene transcription (9) . In addition to the regulation of histones, HDACs can also regulate the acetylation status of a variety of non-histone substrates, including key tumor suppressor proteins and proteins expressed by oncogenes (10) .
Since vorinostat (SAHA) was approved by the US Food and Drug Administration (FDA) for cutaneous T-cell lymphoma in 2006, pharmaceutical chemists have paid increasing attention to HDACis (histone deacetylase inhibitors) in cancer therapy. According to the previous study, we easily find that almost all HDACis have the common pharmacophore, containing three domains. One is ZBG short for the zinc-binding group, such as hydroxamic acid. Another is a cap group, which is generally a hydrophobic and aromatic group. It is a saturated or unsaturated linker domain, composed of linear or cyclic structures that connects the ZBG and the cap group. According to their chemical structures, HDACis can be mainly divided into several classes,
Summary
Histone deacetylases (HDACs) are a family of metal enzymes which mainly regulates the acetylation level of histone, together with histone acetyl transferases (HATs Review including hydroxamic acid, benzamide, carboxylic acid and cyclic peptides (Table 1) . Protein tyrosine kinases can catalyze the transfer of the γ-phosphoryl group on the ATP molecule to the tyrosine residues of substrate proteins, making them phosphorylated (16) . The protein tyrosine kinase family with over 90 members is divided into two subfamilies, the receptor tyrosine kinases (RTKs) and the nonreceptor tyrosine kinases (nRTKs) (Figure 1) (21, 22) . RTKs include EGFR (epidermal growth factor receptor), FGFR (fibroblast growth factor receptor), VEGFR (vascular endothelial growth factor receptor) and so on. nRTKs include Abl, Src and so on. FDA has already approved imatinib, gefitinib, erlotinib, sorafenib, sunitinib, dasatinib, nilotinib, laptinib, and pazopanib for clinical use (Table 2) (23). All of the RTKs are membrane proteins which consist of three parts: an extracellular ligand-binding domain, a transmembrane region and an intracellular kinase domain (22, 24) . After a ligand binds to the extracellular domain, the receptors form dimers stimulating catalytic activity, then several tyrosine residues of the intracellular kinase domain become autophosphorylated. Only autophosphorylated RTKs can activate downstream signaling pathways.
Her (human epidermal growth factor receptor) has four subfamily-EGFR/Her1, Her2-4. EGFR is one typical target for kinase inhibitors in clinical trials. EGFR is a trans-membrane protein belonging to the HER-family of RTKs and can be activated by binding to EGF (epidermal growth factor), TGF-alpha (alphatransforming growth factor) and amphiregulin (34) . The overexpression of both receptors and ligands may lead to uncontrolled activation of signal transduction pathways. However, Her2 has no soluble ligand, which is called an orphan receptor, and it is easier to form heterogeneous dimers with the other three family members. As Table 2 shows, gefitinib, erlotinib, and laptinib mainly target EGFR and Her2.
Numerous combinations of HDACis with other cytotoxic or targeted therapeutics have been tested in clinical trials (Table 3 ). There is no doubt that a synergistic effect really exists for inhibiting these two kinds of targets. For instance, a combination of SAHA and erlotinib cause a synergistic inhibition of cell growth. Tumor cells are potentially vulnerable to HDAC6 inhibition and this has been exploited by combining HDACi with proteosome inhibitors such as bortezomib. In addition, the combined effect of directly targeting oncogenic client proteins using imatinib and destabilizing Bcr-abl by HDACi has a potent antitumor effect in vitro. Moreover, the chemical flexibility of HDACis makes it possible to design multi-targeted small molecules. First of all, HDACis and EGFRis can be simply connected via a linker that can be cleaved under 
Examples of multi-targeting HDACis
CUDC-101 is one successful example in clinical phase I (35, 36) . Cai et al. used a suitable linker to connect the known EGFR/Her2 inhibitor quinazoline with the known HDAC inhibitor hydroxamic acid. They synthesized a series of compounds with CUDC-101 as physiological conditions. In addition, without interfering each other, two individual moieties can be joined through a stable spacer allowing interaction with their proposed targets. Third, two pharmacophores can lead to a single compound whose fragments attack the desired targets without interference. Thus, it is rational to target both histone deacetylase and protein tyrosine kinase. (Table 4) .
To investigate structure activity relationships, compounds were evaluated in EGFR/Her2 kinase and HDAC enzyme assays. The data showed with an increased carbon chain length, HDAC inhibitory activity increased and the optimal length was six. Apparently, the length of the hydroxamic acid side chain was important for HDAC inhibition. Phenyl ring substitutions almost had no effect on HDAC inhibition activity, but larger ones such as compound 10 showed decreased activity. However, the carbon chain length and phenyl ring substitutions were not critical factors that affected EGFR/Her2 activity. Taking the influence of C-7 substitutions into consideration, they chose six carbons as the linker and synthesized compounds 7, 11, 12. When X is O, it was amazing that on one hand, there was no apparent differences for inhibiting HDAC, on the other hand, as for EGFR/Her2 inhibition, OCH 3 was superior to CH 2 CH 2 OCH 3 , which was more efficient than H. Then fixing OCH 3 as R 3 , 7, 13, 14, 15 were compared. 7 (X=O) showed outstanding HDAC inhibition. However, it was a pity that rarely could we tell 7, 13, 14 apart only according to EGFR/Her2 inhibition, indicating that either, sulfide and amide may not be critical. The conjugation of the quinazoline ring with the phenyl ring was disrupted when the length between them was longer. Only compound 17 (Z= CH 2 , R 1 = H, R 2 = H) and 18 (Z = CH 2 , R 1 = F, R 2 = H) were promising on HDAC inhibition. With regard to EGFR/Her2 inhibition, all compounds were inferior to 7. In brief, the changing of an aniline to a benzylamine resulted in less potent compounds. Supposing that the hydroxamic acid side chain position may have an effect on inhibitory activities, 23 and 24 were synthesized and behaved less potently. In conclusion, 7 and 8 were better HDAC, EGFR and Her2 inhibitors. From these conditions, they further evaluated these two compounds against several cancer cell lines, such as NSCLC (nonsmall-cell lung cancer), liver, breast and pancreatic cancer cell lines. Compared with positive control compounds-vorinostat, erlotinib, lapatinib, the combination of vorinostat and erlotinib, and the combination of vorinostat and lapatinib, it is stirring that 8 behaved much better or at least equally (35) .
Cheng-Jung Lai et al. continued to study the antiproliferative effects of 8. They tested the inhibition of HDAC, EGFR and Her2 enzyme activities, indicating nearly the same result. Additionally, by exposing cells to different concentrations of CUDC-101 for 5-24 h, they evaluated the effects in cancer cell lines. Fortunately, CUDC-101 could increase the acetylation of not only histone H3 and H4 but also non-histone substrates such as p53 and ɑ-tubulin, and inhibit the autophosphorylation of EGFR and Her2. This result made it clear that CUDC-101 really targeted HDAC, EGFR, and Her2. The data of growth inhibition in vitro matched what Cai et al. observed. It was encouraging that CUDC-101 displayed a broad activity in vivo xenograft models. In mouse xenograft models, CUDC-101 induced 30% tumor regression and did better than positive control compound erlotinib at a maximum tolerated dose and vorinostat at an equimolar concentration (36) .
In short, in view of its potent drug-like properties and safety, CUDC-101 has already been selected for clinical development. Siavosh Mahboobi et al. designed and synthesized another series of histone deacetylase inhibitors merged with protein tyrosine kinase inhibitors depending on the compound laptinib. SAHA a hydroxamic acid-based HDAC inhibitor has already been approved and MS-275 as a benzamide-HDAC inhibitor has been in phase II clinical trial (Table 1) , so hydroxamic acid and benzamide were chosen to chelate the Zn 2+ . They also changed the substitution patterns from meta to para, altered bioisosteres and explored the effect on the system of vinylogous (Table 5) .
In biochemical, cellular and target-specific assays, they concluded several points. First, hydroxamic acid displayed more potent HDAC inhibition, meanwhile, hydroxamic acid or benzamide were insignificant for EGFR/Her2 inhibition. Second, for HDAC inhibition, bioisosteres and vinylogous were of prime importance and meta surpassed pera. The fact that almost all of the compounds behaved no better than SAHA really depressed everyone. On the contrary, even though bioisosteres, vinylogous and substitution patterns had nothing to do with EGFR/Her2 inhibition, compared to laptinib, each compound showed expectant ability for inhibiting EGFR/Her2. In addition, they also investigated cytotoxicity of these compounds towards some selected cancer cell lines and found that 25a and 25c were the most potential chimeric inhibitors (37) . From these preclinical data, some improvements could be seen noticeably, but HDAC inhibition activity was far from satisfactory. More effort should be made for further development.
Based on the compound imatinib, Siavosh Mahboobi et al. designed and synthesized another series of histone deacetylase inhibitors (Table 6) . In vitro data, benzamide almost showed no HDAC6 inhibition and benzamide was outstripped by hydroxamic acid in inhibiting HDAC1. All the designed compounds were exciting because of their potent inhibition of HDAC. On the contrary, their inhibition of Abl kinase in comparison with imatinib was just passable. The introduction of cellular histone H3 K(Ac) hyperacetylation and cytotoxicity towards HeLa (henrietta lacks strain of In addition, the cytotoxicity of these analogues towards HeLa and K562 cells was in low micromolar or submicromolar range, nevertheless, the potency of imatinib towards K562 cells was superior to that of all designed compounds. Replacing the amine structure with amide resulted in reduced activity. In addition, introduction of a heterocycle decreased Abl kinase inhibition. From the benzene derivatives to pyridine and thiophene derivatives the HDAC1 inhibitory potency decreased. Although 30b, 32b, and 36b showed potent HDAC inhibition, their inhibition of Abl kinase was low grade compared with imatinib (38) . Miao Zuo et al. synthesized N-aryl salicylamides as novel HDAC-EGFR dual inhibitors ( Table 7) . As is known, the length of the hydroxamic acid chain is a key factor for EGFR and HDAC inhibition and the optimal length is six or five. From the data of inhibition activities against EGFR, 39b, 39h, 39i, 39l, 39k, and 39o had strenuous inhibition activities, and the following 4 points were easily found. Comparing 39f, 39m, and 39n, 39f behaved much better just because of the construction of a pseudo six-membered ring. And 39n played no important role. Moreover, it was favorable when R 2 was a methoxy group. Comparing 39o with 39f, there was no doubt that an ether linker was much better than an amide linker, which was also applied to HDAC inhibition. As for HDAC inhibition, it was found that only compound 39n was superior to SAHA. Thus the substitution on the N-phenyl was not vital. The antiproliferative activities were evaluated against human cancer cell lines A431, A549, and HL-60. 39o did best against A431 and A549. At the same time, 39k and 39n exhibited higher potency against HL-60. All in all, N-aryl saliylamides with a hydroxamic acid moiety at the 5-position were promising as HDAC-EGFR dual inhibitors (39) .
Based on erlotinib, Thomas Beckers et al. designed a new series of dual-selective inhibitors (Table 8 ). They tested the inhibition of nuclear extract, cell HDAC and rHDAC1, rHDAC3, rHDAC6 and rHDAC8. 40a-c had no significant inhibition of HDAC. However, 41a-c with substitution at the 7-position achieved a better performance. Compared to SAHA, 41a-c were far from satisfactory. 42a and 42b almost had the same inhibition, showing that exchange of the ethyl group with bromine made no difference. As for 43 and 44, they behaved better and 44 was a great surprise to us with a lower nanomolar inhibition. In view of HDAC inhibition, only 42a, 42b, 43, and 44 were tested for inhibition of EGFR and Her-2 kinase activity. To some extent, all of them inhibited EGFR and HER2, and 42a, 42b, and erlotinib were almost at the same level. Unfortunately, the selectivity profile towards EGFR/Her1 and Her2 did not obviously change.
With regard to cytotoxicity, 42a, 42b, 43, and 44 showed profound activity towards A549 NSCLS cells with 44 being the most promising dual inhibitor (40) .
Xuan Zhang et al. designed other dual-targeted inhibitors (Table 9 ). Owing to the hydroxamic acid being a potent zinc binding group, 45a, 45b, 46a, and 46b with carboxylic acids showed no HDAC inhibition. The ZBG (zinc binding group) location played an important role in unsaturated hydroxamates, while it had no influence on the saturated ones. 48a was the best HDAC inhibitor.
Unfortunately, all the compounds were inferior to lapatinib on EGFR inhibition and Her2 inhibition, suggesting that hydroxamate on the phenyl group negatively affected PTK inhibition. Thus lipophilic ZBG might be worthy of investigation (41).
Conclusions
Recently, HDACis have been recognized as a promising 
